Ganesh Venkataraman Kaundinya
Amministratore Delegato presso GlycoEra AG
Posizioni attive di Ganesh Venkataraman Kaundinya
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
GlycoEra AG
 GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Direttore/Membro del Consiglio | 01/01/2020 | - |
| Amministratore Delegato | 03/05/2022 | - | |
| Presidente | 03/05/2022 | - |
Storia della carriera di Ganesh Venkataraman Kaundinya
Precedenti posizioni note di Ganesh Venkataraman Kaundinya
| Società | Posizione | Inizio | Fine |
|---|---|---|---|
| MOMENTA PHARMACEUTICALS, INC. | Direttore operativo | 25/09/2017 | 05/10/2018 |
| Direttore Tecnico/Scientifico/R&S | 01/01/2002 | 05/10/2018 | |
| Fondatore | 01/05/2001 | 05/10/2018 | |
Consortium for Functional Glycomics
 Consortium for Functional Glycomics Internet Software/ServicesTechnology Services Consortium for Functional Glycomics provides a networking forum and glycomics resources which enable investigators to reveal functions of glycans and glycan-binding proteins. It offers glycan microarray screening services, a reagent bank, and free access to its extensive data repositories and molecule databases. The company was founded in 2001 and is headquartered in La Jolla, CA. | Corporate Officer/Principal | 01/08/2000 | 01/01/2003 |
Harvard University
 Harvard University Other Consumer ServicesConsumer Services Harvard University engages in the provision of teaching and research. It has twelve degree-granting Schools in addition to the Radcliffe Institute for Advanced Study, offering a global education. The university was founded in 1636 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/03/1995 | 01/07/2000 |
Formazione di Ganesh Venkataraman Kaundinya
| Massachusetts Institute of Technology | Doctorate Degree |
Statistiche
Distribuzione geografica
| Stati Uniti | 5 |
| Svizzera | 2 |
Posizioni
| Corporate Officer/Principal | 2 |
| Chief Operating Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
Settori
| Health Technology | 3 |
| Consumer Services | 2 |
| Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
| Aziende private | 3 |
|---|---|
Momenta Pharmaceuticals, Inc.
 Momenta Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Momenta Pharmaceuticals, Inc. operates as a biotechnology company that focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases. Its products include the Glatiramer acetate injection and Enoxaparin Sodium injection. The company was founded by Ram Sasisekharan, Paul R. Schimmel, and Ganesh Venkatraman Kaundinya in May 2001 and is headquartered in Cambridge, MA. | Health Technology |
Consortium for Functional Glycomics
Consortium for Functional Glycomics Internet Software/ServicesTechnology Services Consortium for Functional Glycomics provides a networking forum and glycomics resources which enable investigators to reveal functions of glycans and glycan-binding proteins. It offers glycan microarray screening services, a reagent bank, and free access to its extensive data repositories and molecule databases. The company was founded in 2001 and is headquartered in La Jolla, CA. | Technology Services |
GlycoEra AG
GlycoEra AG BiotechnologyHealth Technology GlycoEra AG is a Swiss biotechnology company specializing in the development of novel biologics for various indications. The company is based in Schlieren, Switzerland, and the USA. The company utilizes its innovative customglycan platform to design, engineer, and develop medicines based on deep expertise in glycobiology. GlycoEra has raised over $49 million in a 2021 series A financing round co-led by 5AM Ventures, Sofinnova Partners, and Roche Venture Fund. The company was founded by Dominique Sirena, Amir Faridmoayer, and Veronica Gambillara Fonck. Ganesh Venkataraman Kaundinya has been the CEO of the company since 2020. | Health Technology |
